REVIEW PAPER
METABOLIC SYNDROME AS A CONSEQUENCE OF ABDOMINAL OBESITY
 
More details
Hide details
1
Z Katedry i Zakładu Medycyny Rodzinnej Uniwersytetu Medycznego w Lublinie
 
Med Og. 2009;15(3):341–350
KEYWORDS
ABSTRACT
Metabolic syndrome is a clustering of cardiovascular risk factors, with insulin resistance as a major feature. This syndrome has been variously defined, but is most often diagnosed with the presence of three or more of the following components: abdominal obesity, hypertension, hypertriglyceridemia, low HDL, and hyperglycaemia. Visceral adipose tissue plays a key role in the pathogenesis of atherosclerosis and insulin resistance, and is closely linked to vascular inflammation. Evaluating for the presence of subclinical atherosclerosis and inflammatory biomarkers may be helpful in the risk stratification of patients with metabolic syndrome. The primary goals of treatment of metabolic syndrome are prevention of coronary heart disease events and type 2 diabetes, if not already present. The approach to treatment of patients with metabolic syndrome should include lifestyle changes, including weight loss and exercise, as well as appriopriate pharmacological therapies.
 
REFERENCES (32)
1.
Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA.: Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002, 156, 1070-7.
 
2.
Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288, 2709-16.
 
3.
Catherine Y , Campbell MD, Khurram Nasir MD, Nathan D, Wong PhD, Roger S, Blumenthal MD.: Role of Atherosclerosis Assesment and Other Novel Markers in the Metabolic Syndrome. Metabolic Syndrome And Related Disorders 2006, 4, 261-269.
 
4.
Tatoń J , Czech A, Bernas M.: Otyłość, zespół metaboliczny. Warszawa: wydawnictwo Lekarskie PZWL 2007, 191-205.
 
5.
Verma A, Boney CH, Tucker R, Vohr BR.: Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. J Clin Endocrinol Metab 2002, 87, 3227-3235.
 
6.
Lauenborg J, Mathiesen E, Hansen T, et al.: The prevalence of the metabolic syndrome in a Danish population of women with previos gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab 2005, 90, 4004-4010.
 
7.
Jasik M, Niebisz A, Kosior D i wsp.: Analiza występowania podwyższonych stężeń cholesterolu całkowitego u chorych na cukrzycę ciężarnych – doniesienie wstępne. Diabetologia Doświadczalna i Kliniczna 2005, 5, 411-416.
 
8.
Marek J.: Rola subklinicznego stanu zapalnego w patogenezie zespołu metabolicznego i cukrzycy typu 2 ze szczególnym uwzględnieniem molekularnych mechanizmów insulinooporności. Medycyna Metaboliczna 2008, XII, 1, 40-54.
 
9.
Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 2003, 107, 391-397.
 
10.
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A , Ross JS , Tartaglia LA, Chen H.: Chronic inflammation in flat plays a crucial role in the development of obesity- related insulin resistance. J Clin Invest 2003, 112, 1821-30.
 
11.
Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A.: Renin- angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension : an integrated view in humans. Hyprtension 2008, 26 (5), 831-843.
 
12.
Harp JB, Henry SA, Di GirolamoM. Dietary weight loss decreases serum angiotensin-converting enzyme activity in obese adults. Obes Res 2002, 10, 985-990.
 
13.
Ford ES, Giles WH, Dietz WH. Prevalance of the metabolic syndrome among Us adults-findings from the Third National Health and Nutrition Examination Survey. JAMA 2002, 287, 356-359.
 
14.
Ford ES.: Prevalance of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28, 2745-2749.
 
15.
Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001, 24, 683-689.
 
16.
Hu FB, Stampfer MJ, Haffner SM, et al.: Elevated risk of cardiovascular diseases mortality prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002, 25, 1129-1134.
 
17.
Wannamethee SG, Shaper AG, Lennon L, Morris RW.: Metabolic syndromevs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch. Intern. Med. 2005, 165, 2644-2650.
 
18.
Kaczmarek M, Tarchalski J.: Zespół metaboliczny – aktualne spojrzenie. Polski Przegląd Kardiologiczny. 2007, 9, 1, 53-58.
 
19.
Bots ML, Hoes AW, Koudstaal PJ, Hoffman A, Grobbee DE.: Common carotid intima-media thickness and risk of stroke and myocardial infarction – the Rotterdam Study. Circulation.1997, 96, 1432-1437.
 
20.
Ali YS, Rembold KE, Weaver B, Wills MB, Tatar S, Ayers CR, Rembold CM.: Prediction of majoradverse cardiovascular events by age-normalized carotid intimal medial thickness. Atherosclerosis 2006, 187, 186-190.
 
21.
Feringa HHH, Bax JJJ, van Waning VH, et al.: The long-term prognostic value of the resting and post exercise ankle-brachial index. Arch Intern Med 2006, 166, 529-535.
 
22.
Resnick HE, Lindsay RS, Mc Dermoit MM, Devereux RB, Jones KL, Fabsitz RR, Howard BV.: Relatonship of high and low ankle-brachial index to all-cause and cardiovascular disease mortality: The Strong Heart Study. Circulation 2004, 109, 733-739.
 
23.
Kondos GT, Hoff JA, Sevrukov A, et al.: Electronbeam tomography coronary artery calcium and cardiac events-a 37- month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 2003, 107, 2571-2576.
 
24.
Greenland P, La Bree L , Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004, 291, 210-215.
 
25.
Santos RD, Nasir K, Johnston P, Carvahlo Ja, Braunstei JB, Blumenthal RS.: Metabolic syndrome provides risk stratification in asymptomatic men considered low risk by Framingham risk estimation. Prevent Cardiol (in press).
 
26.
Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB, Wilson PWF.: C-rective protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004, 110, 380-385.
 
27.
Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen RA.: Cardiovascular disese in US patients with metabolic syndrome, diabetes and elevated C-reactive protein. Diabetes Care 2005, 28, 690-693.
 
28.
Raggi P, Callister TQ, Cooil B, et al.: Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation 2000, 101, 850-855.
 
29.
Grundy SM, Hansen B, Smith SC Jr, et al.: Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung and Blood Institute/ American Diabetes Association conference on scientific issues related to management. Circulation 2004, 109, 67-78.
 
30.
Banach M, Godala M, Krzemińska A.: Postępowanie niefarmakologiczne w przewlekłym leczeniu ambulatoryjnym osób z zespołem matabolicznym po zabiegach PCI i CABG. W: zespół metaboliczny – prewencja i leczenie. Warszawa: Wydawnictwo Medycyna Plus 2006, 67-78.
 
31.
Dziduszko-Fedorko E , Zawadzka-Bysko M.: Rehabilitacja po zabiegach rewaskularyzacji tętnic wieńcowych. Przew. Lek 2004, 7, 18-126.
 
32.
Banach M, Brylski M, Goch A, Kowalski J.: Algorytm postępowania w zespole metabolicznym. Geriatria Polska 2007, 3, 27-48.
 
eISSN:2084-4905
ISSN:2083-4543